Innate, T-, and B-Cell Responses in Acute Human Zika Patients

Clinical Infectious Diseases

Volumn 66, Issue 1, 2018, Pages 1-10

  Lai, Lilin ^a   Rouphael, Nadine ^a   Xu, Yongxian ^a   Natrajan, Muktha S ^a   Beck, Allison ^a   Hart, Mari ^a   Feldhammer, Matthew ^a   Feldpausch, Amanda ^b   Hill, Charles ^a   Wu, Henry ^a   Fairley, Jessica K ^a   Lankford Turner, Pamela ^a   Kasher, Nicole ^a   Rago, Patrick ^a   Hu, Yi Juan ^c   Edupuganti, Srilatha ^a   Patel, Shital M ^d   Murray, Kristy O ^e   Mulligan, Mark J ^a   Domjahn, Briyana ^a   Wang, Dongli ^a   Bower, Mary ^a   Deovic, Rijalda ^a   Aramgam, Sree ^a   Jo Johnson, Sara ^a   Kleinhenz, Dean ^a   Sadowski, JoAnn ^a   Sirajud Deen, Talib ^a   Waggoner, Jesse ^a   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Georgia Department of Public Health   (United States)

^c EMORY UNIVERSITY   (United States)

^d Department of Medicine and Medical Microbiology and Immunology Section of Infectious Diseases   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

flavivirus; immunity; pregnancy; viral persistence; Zika

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 5; PRM PROTEIN; PROTEIN C; PROTEIN E; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS RNA; VIRUS ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MALE; MEMORY CELL; MONOCYTE COUNT; NONHUMAN; PLASMABLAST; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRAVEL; UNITED STATES; ZIKA FEVER; ZIKA VIRUS; ADAPTIVE IMMUNITY; BLOOD; CASE REPORT; IMMUNOLOGY; PATHOLOGY; PREGNANCY; T LYMPHOCYTE SUBPOPULATION; TIME FACTOR; VIROLOGY; VIRUS LOAD;

ADAPTIVE IMMUNITY; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULIN M; MALE; PREGNANCY; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; TIME FACTORS; VIRAL LOAD; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85040577295     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix732     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases. Zika Virus Reporting and Surveillance. Available at: Https://www.cdc.gov/zika/reporting/case-counts.html. Accessed 16 May 2017.
2. Brasil P, Pereira JP Jr, Moreira ME, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med 2016; 375:2321-34.
3. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects-reviewing the evidence for causality. N Engl J Med 2016; 374:1981-7.
4. Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy-Brazil, 2015. Morb Mortal Wkly Rep 2016; 65:242-7.
5. Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill 2014; 19.
6. Broutet N, Krauer F, Riesen M, et al. Zika virus as a cause of neurologic disorders. N Engl J Med 2016; 374:1506-9.
7. Mécharles S, Herrmann C, Poullain P, et al. Acute myelitis due to Zika virus infection. Lancet 2016; 387:1481.
8. Aletti M, Lecoules S, Kanczuga V, et al. Transient myocarditis associated with acute Zika virus infection. Clin Infect Dis 2017; 64:678-9.
9. Waggoner JJ, Rouphael N, Xu Y, et al. Pericarditis associated with acute Zika virus infection in a returning traveler. Open Forum Infect Dis 2017; 4:ofx103.
10. Abbink P, Larocca RA, De La Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 2016; 353:1129-32.
11. Cohen J. Infectious disease. The race for a Zika vaccine is on. Science 2016; 351:543-4.
12. Dowd KA, Ko SY, Morabito KM, et al. Rapid development of a DNA vaccine for Zika virus. Science 2016; 354:237-40.
13. Lipsitch M, Cowling BJ. Zika vaccine trials. Science 2016; 353:1094-5.
14. Osterholm MT. Ebola and Zika: Cautionary tales. Science 2016; 353:1073.
15. Dudley DM, Aliota MT, Mohr EL, et al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat Commun 2016; 7:12204.
16. Dowd KA, DeMaso CR, Pelc RS, et al. Broadly neutralizing activity of Zika virus-immune sera identifies a single viral serotype. Cell Rep 2016; 16:1485-91.
17. Pierson TC, Graham BS. Zika virus: Immunity and vaccine development. Cell 2016; 167:625-31.
18. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids-preliminary report. N Engl J Med 2017. doi: 10.1056/NEJMoa1613108.
19. Kwissa M, Nakaya HI, Onlamoon N, et al. Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 2014; 16:115-27.
20. Edupuganti S, Eidex RB, Keyserling H, et al; YF-Ig Study Team. A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: Comparative viremia and immunogenicity. Am J Trop Med Hyg 2013; 88:172-7.
21. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis 2008; 14:1232-9.
22. Murray KO, Gorchakov R, Carlson AR, et al. Prolonged detection of Zika virus in vaginal secretions and whole blood. Emerg Infect Dis 2017; 23:99-101.
23. Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 2016; 113:7852-7.
24. Centers for Disease Control and Prevention. Zika MAC-ELISA. Instructions for Use, 2016. Available at http://www.cdc.gov/zika/pdfs/zika-mac-elisa-instructions-for-use.pdf. Accessed 13 May 2017.
25. Lustig Y, Mendelson E, Paran N, Melamed S, Schwartz E. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. Euro Surveill 2016; 21.
26. Rios M, Daniel S, Chancey C, Hewlett IK, Stramer SL. West Nile virus adheres to human red blood cells in whole blood. Clin Infect Dis 2007; 45:181-6.
27. Lanteri MC, Lee TH, Wen L, et al. West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: Implication for transfusion and transplantation safety. Transfusion 2014; 54:3232-41.
28. Meaney-Delman D, Oduyebo T, Polen KN, et al; U.S. Zika Pregnancy Registry Prolonged Viremia Working Group. Prolonged detection of Zika virus RNA in pregnant women. Obstet Gynecol 2016; 128:724-30.
29. Schmid MA, Diamond MS, Harris E. Dendritic cells in dengue virus infection: Targets of virus replication and mediators of immunity. Front Immunol 2014; 5:647.
30. Hamel R, Dejarnac O, Wichit S, et al. Biology of Zika virus infection in human skin cells. J Virol 2015; 89:8880-96.
31. Bowen JR, Quicke KM, Maddur MS, et al. Zika virus antagonizes type I interferon responses during infection of human dendritic cells. PLoS Pathog 2017; 13:e1006164.
32. Chandele A, Sewatanon J, Gunisetty S, et al. Characterization of human CD8 T cell responses in dengue virus-infected patients from India. J Virol 2016; 90:11259-78.
33. McElroy AK, Akondy RS, Davis CW, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA 2015; 112:4719-24.
34. Poland JD, Calisher CH, Monath TP, Downs WG, Murphy K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59:895-900.
35. Feroldi E, Boaz M, Yoksan S, et al. Persistence of wild-type Japanese encephalitis virus strains cross-neutralization 5 years after JE-CV immunization. J Infect Dis 2017; 215:221-7.
36. Edupuganti S, Natrajan MS, Rouphael N, et al. Biphasic Zika illness with rash and joint pain. Open Forum Infect Dis 2017; 4:ofx133. In press.
37. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512.
38. Ndhlovu ZM, Kamya P, Mewalal N, et al. Magnitude and kinetics of CD8+ T cell activation during hyperacute HIV infection impact viral set point. Immunity 2015; 43:591-604.
39. Rivino L, Kumaran EA, Jovanovic V, et al. Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol 2013; 87:2693-706.
40. Turtle L, Bali T, Buxton G, et al. Human T cell responses to Japanese encephalitis virus in health and disease. J Exp Med 2016; 213:1331-52.